How large is the positron emission tomography (pet) radiotracer market, and what is its growth trajectory?
The positron emission tomography (PET) radiotracer market size has grown strongly in recent years. It will grow from $2.35 billion in 2024 to $2.57 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to the increasing prevalence of infectious diseases, increasing awareness and accessibility, the emergence of novel radiotracers, the rising prevalence of cancer, and the increasing focus on preventive medicine.
The positron emission tomography (PET) radiotracer market size is expected to see strong growth in the next few years. It will grow to $3.63 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to the expansion of applications, regulatory approvals, growth in emerging markets, growing geriatric population, and growing adoption of PET radio scanners. Major trends in the forecast period include the development of micro-pet technology, integration with wearable technology, expansion of theranostics, nano-radiotracers, and blockchain for data security.
Get Your Free Sample of The Global Positron Emission Tomography (PET) Radiotracer Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19152&type=smp
What are the key forces behind the positron emission tomography (pet) radiotracer market’s growth in recent years?
The increasing prevalence of infectious diseases is expected to propel the growth of the positron emission tomography (PET) radiotracer market going forward. Infectious diseases refer to illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. The rising prevalence of infectious diseases is due to climate change, urbanization, globalization, antibiotic resistance, and changes in human behavior, which all facilitate the spread of pathogens. Positron emission tomography (PET) radiotracers help infectious diseases by visualizing metabolic activity and inflammation, enabling detection of infection, assessment of treatment response, and differentiation between infectious and non-infectious conditions for better patient outcomes. For instance, in February 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, tuberculosis (TB) cases in England increased by 10.7% in 2023, with 4,850 cases reported compared to 4,380 in 2022. Therefore, the increasing prevalence of infectious diseases is driving the growth of the positron emission tomography (PET) radiotracer market.
What are the major segments of the positron emission tomography (pet) radiotracer market?
The positron emission tomography (PET) radiotracer market covered in this report is segmented –
1) By Radiotracer Type: F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), Other Radiotracer Types
2) By Application: Cancer, Heart Disease, Gastrointestinal, Endocrine, Neurological Disorders, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Other End-Users
Subsegments:
1) By F-18 (Fluorodeoxyglucose 18): F-18 FDG (Fluorodeoxyglucose), F-18 Fluoroethyltyrosine (FET), F-18 Florbetapir (Amyloid PET Imaging)
2) By Ga-68 (Fibroblast Activation Protein Inhibitor): Ga-68 Dotatate (Neuroendocrine Tumor Imaging), Ga-68 PSMA (Prostate-Specific Membrane Antigen Imaging), Ga-68 FAPI (Fibroblast Activation Protein Inhibitor Imaging)
3) By Other Radiotracer Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Rb-82 (Rubidium-82), I-124 (Iodine-124)
Order your report now for swift delivery
Which companies dominate the positron emission tomography (pet) radiotracer market?
Major companies operating in the positron emission tomography (PET) radiotracer marker are Cardinal Health Inc., AstraZeneca PLC, Eli Lilly and Company, Siemens Healthineers AG, GE Healthcare Technologies Inc., Philips Healthcare, Bracco Imaging S.p.A., Neusoft Medical Systems Co Ltd., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences (SOFIE), Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., RefleXion Medical Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., IXICO PLC, ImaginAb Inc., Radiomedix Inc.
What major trends will shape the positron emission tomography (pet) radiotracer market during the forecast period?
Major companies operating in the positron emission tomography (PET) radiotracer market are focusing on developing advanced diagnostic solutions, such as positron emission tomography imaging agents to enhance cancer detection and improve patient outcomes. A positron emission tomography (PET) imaging agent refers to a radioactive substance used to visualize and measure biological processes in the body during PET scans. For instance, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canada-based radiopharmaceutical company, launched Illuccix, also known as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada as a prostate cancer imaging agent designed to detect metastatic prostate cancer. This tool is valuable for physicians in identifying metastatic disease and aiding in patient management decisions. It is indicated for use in patients suspected of having metastasis who are candidates for initial definitive therapy, as well as in those with suspected recurrence indicated by elevated serum prostate-specific antigen (PSA) levels.
What are the key regional dynamics of the positron emission tomography (pet) radiotracer market, and which region leads in market share?
North America was the largest region in the positron emission tomography (PET) radiotracer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (PET) radiotracer marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Positron Emission Tomography (PET) Radiotracer Market Report 2025 Offer?
The positron emission tomography (pet) radiotracer market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A positron emission tomography (PET) radiotracer refers to a radioactive substance used in positron emission tomography (PET) imaging. A PET radiotracer is utilized by injecting a patient with a radioactive substance that binds to specific biological targets, allowing the PET scanner to visualize metabolic activity and diagnose conditions such as cancer or neurological disorders.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19152
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
